Analytical Data
-
基因名
UGT1A1
- Application
-
别名
UGT1A1；GNT1；UDP-glucuronosyltransferase 1A1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P22309
-
表达区间
25-490aa
-
氨基酸序列
MGSSHHHHHHSSGLVPRGSHMGSHAGKILLIPVDGSHWLSMLGAIQQLQQ RGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFEN DSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDP FLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSD HMTFLQRVKNMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSAS VWLFRSDFVKDYPRPIMPNMVFVGGINCLHQNPLSQEFEAYINASGEHGI VVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILV KWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAK RMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPV EPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLD
-
分子量
55 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UGT1A1 (UDP-glucuronosyltransferase 1A1) is an important enzyme in the human liver, primarily responsible for the glucuronidation process, which facilitates the metabolism and excretion of a wide variety of endogenous and exogenous substances, including bilirubin, hormones, and drugs. Mutations and polymorphisms in the UGT1A1 gene can lead to impaired enzyme activity, resulting in conditions such as Gilbert's syndrome and Crigler-Najjar syndrome, which are characterized by elevated bilirubin levels and potential liver damage. Due to its crucial role in drug metabolism, UGT1A1 also significantly influences pharmacokinetics and pharmacodynamics, affecting drug efficacy and toxicity. Therefore, the study of UGT1A1 recombinant protein is vital for understanding its functional mechanisms, potential drug interactions, and genetic variability in populations. The production of UGT1A1 as a recombinant protein allows for detailed biochemical studies, enabling researchers to analyze its structure, substrate specificity, and the effects of various inhibitors or inducers. Such research is not only essential for elucidating the enzyme's role in metabolism but also holds promise for developing personalized medicine approaches, optimizing drug therapy, and improving patient outcomes. As drug regimens are increasingly tailored to individual genetic profiles, understanding UGT1A1's function through recombinant protein studies provides a foundation for advancing pharmacogenomics and enhances our ability to predict responses to therapeutic agents based on genetic variations.
